Journal article icon

Journal article

Long-term psychological and neurological outcomes among people with a history of non-malignant meningioma in the UK Biobank cohort

Abstract:
Background: Meningiomas are among the most common brain tumours in the United Kingdom and incidence is increasing. Up to 90% of meningiomas are Grade 1 (non-malignant) and have high survival. Brain tumour survivors are at risk of psychological and neurological late effects but risks in persons with non-malignant meningioma are not well characterized. Methods: We used UK Biobank, a cohort of approximately 500 000 adults recruited ages 40-69 during 2006-2010. Non-malignant meningioma patients were identified through linked cancer registry data. Follow-up for 10 outcomes was based on linkage to Hospital Episode Statistics. Standardized incidence ratios (SIRs) compared risks in meningioma patients to rates from UK Biobank overall, adjusted for age, sex, and calendar time. Results: Four hundred and sixty-seven individuals were diagnosed with non-malignant meningioma after joining UK Biobank (77% female). Median age at diagnosis was 65 and median follow-up was 5 years. Persons with meningioma had significantly increased risks of 9 of 10 sequelae studied. The lowest SIR was for stroke (1.3, 95% confidence interval [CI] 0.6-2.9) and the highest SIRs were for epilepsy (18.9, 95%CI: 13.3-26.9) and visual disturbances (6.6, 95%CI: 3.3-13.1). SIRs for depression, anxiety, headache, fatigue, hearing loss, limb weakness, and cognitive issues (in ascending order) ranged from 2.3 (95%CI: 1.6-3.4) to 4.4 (95%CI: 2.8-6.9). Conclusions: By providing preliminary evidence of excess risk of a range of long-term sequelae, this research can provide insight into future risks and validate survivor experience for people diagnosed with non-malignant meningioma and build momentum for future research using larger population-based databases and primary care records.
Publication status:
Published
Peer review status:
Peer reviewed

Actions

Access Document

Files:
Publisher copy:
10.1093/noajnl/vdaf105

Authors

More by this author
Institution:
University of Oxford
Role:
Author
ORCID:
0000-0002-9757-040X
More by this author
Institution:
University of Oxford
Role:
Author
More by this author
Role:
Author
ORCID:
0000-0002-6775-5251
More by this author
Role:
Author
ORCID:
0000-0001-5364-8757
More by this author
Role:
Author
ORCID:
0000-0003-2597-9510


Publisher:
Oxford University Press
Journal:
Neuro-Oncology Advances More from this journal
Volume:
7
Issue:
1
Article number:
vdaf105
Publication date:
2025-06-05
DOI:
EISSN:
2632-2498
ISSN:
2632-2498


Language:
English
Keywords:
Pubs id:
2130255
Local pid:
pubs:2130255
Source identifiers:
3138878
Deposit date:
2025-07-23
ARK identifier:
This ORA record was generated from metadata provided by an external service. It has not been edited by the ORA Team.

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP